DK2913407T3 - Fremgangsmåde til at detektere human papillomavirus mRNA - Google Patents
Fremgangsmåde til at detektere human papillomavirus mRNA Download PDFInfo
- Publication number
- DK2913407T3 DK2913407T3 DK15158266.5T DK15158266T DK2913407T3 DK 2913407 T3 DK2913407 T3 DK 2913407T3 DK 15158266 T DK15158266 T DK 15158266T DK 2913407 T3 DK2913407 T3 DK 2913407T3
- Authority
- DK
- Denmark
- Prior art keywords
- hpv
- dna
- artificial sequence
- primer
- nasba
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 162
- 238000000034 method Methods 0.000 title claims abstract description 94
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 144
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 58
- 238000012216 screening Methods 0.000 claims abstract description 52
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 90
- 230000003321 amplification Effects 0.000 claims description 74
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 42
- 230000003902 lesion Effects 0.000 claims description 22
- 238000011161 development Methods 0.000 claims description 20
- 238000003745 diagnosis Methods 0.000 claims description 13
- 108700026244 Open Reading Frames Proteins 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 101150071673 E6 gene Proteins 0.000 claims description 10
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 claims description 9
- 206010059313 Anogenital warts Diseases 0.000 claims description 8
- 238000011897 real-time detection Methods 0.000 claims description 7
- 238000011895 specific detection Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 698
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 687
- 239000013615 primer Substances 0.000 description 431
- 108020004414 DNA Proteins 0.000 description 403
- 239000000523 sample Substances 0.000 description 224
- 210000004027 cell Anatomy 0.000 description 130
- 238000001514 detection method Methods 0.000 description 72
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 49
- 206010008263 Cervical dysplasia Diseases 0.000 description 49
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 47
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 38
- 229930010555 Inosine Natural products 0.000 description 37
- 229960003786 inosine Drugs 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 34
- 108091034117 Oligonucleotide Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108020004707 nucleic acids Proteins 0.000 description 33
- 230000035945 sensitivity Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
- 238000001574 biopsy Methods 0.000 description 20
- 239000002987 primer (paints) Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000000137 annealing Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 15
- 210000003679 cervix uteri Anatomy 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 12
- 208000009608 Papillomavirus Infections Diseases 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108700020796 Oncogene Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 10
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 10
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 8
- 101710106597 U1 small nuclear ribonucleoprotein A Proteins 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000012139 lysis buffer Substances 0.000 description 8
- 238000009595 pap smear Methods 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 8
- 241000341655 Human papillomavirus type 16 Species 0.000 description 7
- 101150075239 L1 gene Proteins 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000002380 cytological effect Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 238000002573 colposcopy Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000009826 neoplastic cell growth Effects 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical group C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 101710121996 Hexon protein p72 Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 description 2
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 101100163433 Drosophila melanogaster armi gene Proteins 0.000 description 2
- 101150082674 E2 gene Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 241001061257 Emmelichthyidae Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000617779 Homo sapiens U1 small nuclear ribonucleoprotein A Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 1
- 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000018165 U1 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 108010091281 U1 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 101150014333 U1A gene Proteins 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000025358 tongue carcinoma Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (9)
1. In vitro fremgangsmåde til at screene humane individer for at vurdere deres risiko for at udvikle cervikal carcinoma, hvilken fremgangsmåde omfatter at screene individet for ekspression af fuldlængde mRNA transskripter af E6-genet af HPV og at sortere individet i en af to risikokategorier for udvikling af cervikal carcinoma baseret på ekspression af nævnte E6 mRNA, hvori individer, som er positive for ekspression af E6 mRNA, mærkes som bærer af integreret HPV eller et modificeret episomal HPV genom og derfor klassificeres som havende høj risiko for udvikling af cervikal carcinoma, hvorimod individer, som er negative for ekspression af E6 mRNA, mærkes som ikke-bærer af integreret HPV eller et modificeret episomal HPV genom og derfor klassificeres som havende ikke-detekterbar risiko for udvikling af cervikal carcinoma.
2. Fremgangsmåde ifølge krav 1, hvori de humane individer er individer, der tidligere er identificeret som inficeret med human papillomavirus DNA i cervixceller.
3. Fremgangsmåde ifølge krav 1, hvori de humane individer er individer med en tidligere ASCUS diagnose, CIN 1 læsioner eller kondylom.
4. Fremgangsmåde ifølge ethvert af kravene 1 til 3, som omfatter at screene for fuldlængde E6 mRNA-ekspression ved at anvende en teknik, som er i stand til at detektere fuldlængde E6 mRNA fra mindst én cancerassocieret HPV type.
5. Fremgangsmåde ifølge krav 4, som omfatter at screene for fuldlængde E6 mRNA-ekspression ved at anvende af en teknik, som er i stand til at detektere fuldlængde E6 mRNA fra HPV type 16.
6. Fremgangsmåde ifølge krav 5, hvori fuldlængde E6 mRNA transskripter fra HPV type indeholder hele regionen fra nukleotid 97 til 880 i den E6-åbne læseramme, indbefattende nucleotiderne 97 og 880.
7. Fremgangsmåde ifølge krav 6, som omfatter specifik detektering af fuldlængde transkripter af HPV type 16 ved at anvende en amplifikationsteknik med primere, der er specifikke specifikt for et område, der kun er til stede i nævnte fuldlængde transkripter.
8. Fremgangsmåde ifølge ethvert af kravene 1 til 7, hvori at screene for E6 mRNA-ekspression udføres ved at anvende en amplifikationsreaktion til at amplificere et område af mRNA’en samtidig med realtidsdetektering af amplifikationreaktionens produkter.
9. Fremgangsmåde ifølge krav 8, hvori at screene for E6 mRNA ekspression udføres ved at anvende realtid-NASBA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0200239A GB0200239D0 (en) | 2002-01-07 | 2002-01-07 | Method for detecting human papillomavirus mRNA |
| GB0214124A GB0214124D0 (en) | 2002-06-19 | 2002-06-19 | Method for detecting human papillomavirus mRNA |
| EP06075498.3A EP1715062B1 (en) | 2002-01-07 | 2003-01-07 | Method for detecting human papillomavirus mRNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2913407T3 true DK2913407T3 (da) | 2018-01-15 |
Family
ID=26246916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15158266.5T DK2913407T3 (da) | 2002-01-07 | 2003-01-07 | Fremgangsmåde til at detektere human papillomavirus mRNA |
| DK03700338T DK1463839T3 (da) | 2002-01-07 | 2003-01-07 | Fremgangsmåde til detektering af human papillomavirus mRNA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03700338T DK1463839T3 (da) | 2002-01-07 | 2003-01-07 | Fremgangsmåde til detektering af human papillomavirus mRNA |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7553623B2 (da) |
| EP (5) | EP2267155B2 (da) |
| JP (2) | JP4558322B2 (da) |
| CN (1) | CN100422342C (da) |
| AT (1) | ATE354677T1 (da) |
| AU (2) | AU2003201639C1 (da) |
| BR (1) | BR0306723A (da) |
| CA (1) | CA2472026A1 (da) |
| CY (1) | CY1106621T1 (da) |
| DE (1) | DE60311961T2 (da) |
| DK (2) | DK2913407T3 (da) |
| EA (1) | EA006975B1 (da) |
| ES (2) | ES2654909T3 (da) |
| IL (2) | IL162722A0 (da) |
| MX (1) | MXPA04006440A (da) |
| NO (1) | NO20042769L (da) |
| NZ (1) | NZ533703A (da) |
| PT (1) | PT1463839E (da) |
| SI (1) | SI1463839T1 (da) |
| WO (1) | WO2003057914A2 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US20110111389A1 (en) * | 2001-11-07 | 2011-05-12 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis for human papillomavirus and the device thereof |
| EP2267155B2 (en) | 2002-01-07 | 2016-09-07 | Norchip A/S | Method for detecting human papillomavirus mRNA |
| EP1369694A1 (en) * | 2002-04-09 | 2003-12-10 | MTM Laboratories AG | Method for discrimination of metaplasias from neoplastic or preneoplastic lesions |
| US7741031B2 (en) * | 2003-03-07 | 2010-06-22 | The Public Health Research Institute Of The City Of New York | Optically decodable microcarries, arrays and methods |
| US7361460B2 (en) * | 2003-04-11 | 2008-04-22 | Digene Corporation | Approach to molecular diagnosis of human papillomavirus-related diseases |
| EP1510820B1 (en) * | 2003-08-25 | 2010-03-17 | MTM Laboratories AG | Method for detecting medically relevant conditions in a solubilized LBC sample |
| ATE289685T1 (de) * | 2003-08-25 | 2005-03-15 | Mtm Lab Ag | Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben |
| EP1664348B8 (en) * | 2003-09-25 | 2019-06-12 | Third Wave Technologies, Inc. | Detection of hpv |
| WO2005033333A2 (en) | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
| WO2005062940A2 (en) | 2003-12-22 | 2005-07-14 | John Wayne Cancer Institute | Method and apparatus for in vivo collection and surveillance of circulating biological components |
| GB0404315D0 (en) * | 2004-02-26 | 2004-03-31 | Norchip As | Improved detection of human papillomavirus |
| ITMO20040126A1 (it) | 2004-05-21 | 2004-08-21 | Bioanalisi Ct Sud S N C Di Per | Sistema per la ricerca ed identificazione di agenti patogeni |
| WO2006137939A2 (en) | 2004-11-09 | 2006-12-28 | Gen-Probe Incorporated | Compositions and methods for detecting group a streptococci |
| EP1819835B1 (en) | 2004-12-08 | 2010-08-04 | Gen-Probe Incorporated | Detection of nucleic acids from multiple types of human papillomaviruses |
| DK2500439T4 (da) | 2005-06-20 | 2017-11-13 | Advanced Cell Diagnostics Inc | Kits og produkter til detektering af nukleinsyrer i individuelle celler og til identifikation af sjældne celler fra store heterogene cellepopulationer |
| EP1844164B1 (en) * | 2005-11-15 | 2010-07-14 | Genoid KFT | Method of detecting pathogens using molecular beacons |
| WO2007115582A1 (en) | 2006-04-11 | 2007-10-18 | Bio-Rad Pasteur | Hpv detection and quantification by real-time multiplex amplification |
| US7833716B2 (en) * | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| US20100285443A1 (en) * | 2006-12-15 | 2010-11-11 | Oncomethylome Sciences Sa | Diagnostic Methods for Diseases Caused by a HPV Infection Comprising Determining the Methylation Status of the HPV Genome |
| EP3095873B1 (en) | 2006-12-21 | 2018-04-18 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
| US7838215B2 (en) * | 2007-09-25 | 2010-11-23 | Canvir, Inc. | Advanced cervical cell screening methods |
| US9435001B2 (en) | 2007-11-01 | 2016-09-06 | Self-Screen B.V. | Detection method for cervical HPVS |
| JP5299986B2 (ja) * | 2007-11-01 | 2013-09-25 | 国立大学法人山口大学 | 核酸の定量方法 |
| CA2726396C (en) * | 2008-04-17 | 2019-03-19 | Qiagen Gaithersburg, Inc. | Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid |
| US9090948B2 (en) * | 2008-09-30 | 2015-07-28 | Abbott Molecular Inc. | Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples |
| TWI419974B (zh) | 2008-10-27 | 2013-12-21 | Qiagen Gaithersburg Inc | 於自動平台上之快速結果雜交捕捉法 |
| EP2184368A1 (en) | 2008-11-07 | 2010-05-12 | DKFZ Deutsches Krebsforschungszentrum | Diagnostic transcript and splice patterns of HPV16 in different cervical lesions |
| WO2010127228A1 (en) * | 2009-05-01 | 2010-11-04 | Qiagen Gaithersburg, Inc. | A non-target amplification method for detection of rna splice-forms in a sample |
| JP5826752B2 (ja) * | 2009-09-14 | 2015-12-02 | キアジェン ゲイサーズバーグ インコーポレイテッド | 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法 |
| AU2011203450B2 (en) * | 2010-01-04 | 2016-01-07 | Qiagen Gaithersburg, Inc. | Methods, compositions, and kits for recovery of nucleic acids or proteins from fixed tissue samples |
| JP2013517803A (ja) | 2010-01-29 | 2013-05-20 | キアジェン ゲイサーズバーグ インコーポレイテッド | サンプル中のｈｐｖの存在を決定および確認する方法 |
| CA2787924A1 (en) * | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| US20110275698A1 (en) * | 2010-05-10 | 2011-11-10 | Norchip A/S | "test and treat" strategy for treating transforming hpv infection |
| EP2572001A2 (en) | 2010-05-19 | 2013-03-27 | QIAGEN Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| US8658361B2 (en) | 2010-10-21 | 2014-02-25 | Advanced Cell Diagnostics, Inc. | Ultra sensitive method for in situ detection of nucleic acids |
| BR112013017489B1 (pt) * | 2011-01-07 | 2021-06-08 | Qiagen Gaithersburg, Inc | "métodos para genotipagem de hpv de alto risco e para distinguir entre infecções por hpv 16, hpv 18 e hpv 45". |
| EP2668290B1 (en) * | 2011-01-28 | 2017-05-31 | Advanced Cell Diagnostics, Inc. | Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions |
| WO2012116220A2 (en) | 2011-02-24 | 2012-08-30 | Qiagen Gaithersburg, Inc. | Materials and methods for detection of hpv nucleic acid |
| US20130095474A1 (en) * | 2011-10-13 | 2013-04-18 | Joseph Mamone | Design of stem-loop probes and utilization in snp genotyping |
| ES2730711T3 (es) | 2011-11-03 | 2019-11-12 | Qiagen Gaithersburg Inc | Materiales y métodos para inmovilizar, aislar y concentrar células usando superficies carboxiladas |
| CN102864224A (zh) * | 2012-09-11 | 2013-01-09 | 南京大学 | 一种血清microRNAs试剂盒及其应用 |
| GB201310933D0 (en) | 2013-06-19 | 2013-07-31 | Norchip As | A method of cervical screening |
| CA2932859A1 (en) * | 2013-12-05 | 2015-06-11 | Optipharm. Co., Ltd. | Improved cervical cancer diagnosing method and diagnostic kit for same |
| WO2016005789A1 (en) * | 2014-07-07 | 2016-01-14 | Institut Pasteur | Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus- associated cancer stages |
| CN106048014B (zh) * | 2016-06-07 | 2019-12-10 | 博奥生物集团有限公司 | 一种用于实时检测nasba产物的高特异探针 |
| US20190112673A1 (en) * | 2017-05-10 | 2019-04-18 | Genomic Vision | Association between integration of high-risk hpv genomes detected by molecular combing and the severity and/or clinical outcome of cervical lesions |
| JP6831772B2 (ja) | 2017-12-22 | 2021-02-17 | 株式会社Ｓｕｂａｒｕ | 画像投影装置 |
| CN114214343A (zh) * | 2021-11-15 | 2022-03-22 | 上海市东方医院（同济大学附属东方医院） | 一组高危型HPV整合所致的宫颈癌中特异表达的mRNA序列 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE76429T1 (de) | 1986-03-21 | 1992-06-15 | Pasteur Institut | Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen. |
| EP0357611B1 (en) * | 1987-02-26 | 1995-04-26 | The University Of Sydney | A method of detection of carcinogenic human papillomavirus |
| US5182377A (en) | 1988-09-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Probes for detection of human papillomavirus |
| US5639871A (en) * | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| DE3838269A1 (de) * | 1988-11-11 | 1990-05-17 | Behringwerke Ag | Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen |
| NL8900725A (nl) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
| US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| JP2791685B2 (ja) | 1989-06-08 | 1998-08-27 | 寳酒造株式会社 | パピローマウイルスの検出方法 |
| US5580970A (en) * | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
| DE69033850T2 (de) * | 1989-12-01 | 2002-06-06 | Vysis, Inc. | Nukleinsäuresonden zum Nachweis von HPV-Transkripts |
| NL9000134A (nl) | 1990-01-19 | 1991-08-16 | Stichting Res Fonds Pathologie | Primers en werkwijze voor het detecteren van humaan papilloma virus genotypen m.b.v. pcr. |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5506105A (en) * | 1991-12-10 | 1996-04-09 | Dade International Inc. | In situ assay of amplified intracellular mRNA targets |
| WO1994026934A2 (en) * | 1993-05-06 | 1994-11-24 | Baxter Diagnostics Inc. | Human papillomavirus detection assay |
| US6174668B1 (en) * | 1993-05-14 | 2001-01-16 | Johnson & Johnson Clinical Diagnostics, Inc. | Diagnostic compositions, elements, methods and test kits for amplification and detection of two or more target DNA's using primers having matched melting temperatures |
| DK1921169T3 (da) | 1993-11-12 | 2012-06-04 | Phri Properties Inc | Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits |
| DE4431174A1 (de) * | 1994-09-01 | 1996-03-07 | Deutsches Krebsforsch | Nachweisverfahren für tumorspezifische mRNA |
| DE19506561C1 (de) * | 1995-02-24 | 1996-10-10 | Deutsches Krebsforsch | Verfahren zur Früherkennung von HPV-assoziierten Karzinomen bzw. von hochgradigen, durch HPV-verursachten Dysplasien |
| AU726047B2 (en) | 1995-11-15 | 2000-10-26 | Gen-Probe Incorporated | Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits |
| US6027981A (en) | 1997-10-27 | 2000-02-22 | Texas Instruments - Acer Incorporated | Method for forming a DRAM cell with a fork-shaped capacitor |
| CA2313641A1 (en) | 1997-12-12 | 1999-06-24 | Digene Corporation | Universal collection medium |
| AU4515699A (en) | 1998-06-26 | 2000-01-17 | Akzo Nobel N.V. | Tagging of rna amplicons generated by transcription-based amplification |
| AU2001249526A1 (en) | 2000-03-28 | 2001-10-08 | Biosearch International Pty Ltd | Approaches for hpv detection and staging by targeting the e6 gene region of the viral genome |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0018050D0 (en) * | 2000-07-21 | 2000-09-13 | Norchip As | Detection of human papillomavirus mRNA |
| ES2276948T3 (es) * | 2001-08-23 | 2007-07-01 | MERCK & CO., INC. | Ensayos pcr de hp multiplex fluorescente que usan fluoforos multiples. |
| GB0200258D0 (en) * | 2002-01-07 | 2002-02-20 | Norchip As | Detection of human papillomavirus |
| EP2267155B2 (en) * | 2002-01-07 | 2016-09-07 | Norchip A/S | Method for detecting human papillomavirus mRNA |
| GB0404315D0 (en) | 2004-02-26 | 2004-03-31 | Norchip As | Improved detection of human papillomavirus |
-
2003
- 2003-01-07 EP EP10184669.9A patent/EP2267155B2/en not_active Expired - Lifetime
- 2003-01-07 EP EP03700338A patent/EP1463839B1/en not_active Expired - Lifetime
- 2003-01-07 CN CNB038053802A patent/CN100422342C/zh not_active Expired - Fee Related
- 2003-01-07 NZ NZ533703A patent/NZ533703A/en not_active IP Right Cessation
- 2003-01-07 AT AT03700338T patent/ATE354677T1/de active
- 2003-01-07 DK DK15158266.5T patent/DK2913407T3/da active
- 2003-01-07 PT PT03700338T patent/PT1463839E/pt unknown
- 2003-01-07 ES ES15158266.5T patent/ES2654909T3/es not_active Expired - Lifetime
- 2003-01-07 WO PCT/GB2003/000034 patent/WO2003057914A2/en not_active Ceased
- 2003-01-07 EA EA200400919A patent/EA006975B1/ru not_active IP Right Cessation
- 2003-01-07 EP EP06075498.3A patent/EP1715062B1/en not_active Expired - Lifetime
- 2003-01-07 SI SI200330775T patent/SI1463839T1/sl unknown
- 2003-01-07 DK DK03700338T patent/DK1463839T3/da active
- 2003-01-07 AU AU2003201639A patent/AU2003201639C1/en not_active Ceased
- 2003-01-07 JP JP2003558207A patent/JP4558322B2/ja not_active Expired - Fee Related
- 2003-01-07 EP EP10184464A patent/EP2272988A3/en not_active Withdrawn
- 2003-01-07 ES ES03700338T patent/ES2282599T3/es not_active Expired - Lifetime
- 2003-01-07 US US10/500,832 patent/US7553623B2/en not_active Expired - Fee Related
- 2003-01-07 MX MXPA04006440A patent/MXPA04006440A/es active IP Right Grant
- 2003-01-07 DE DE60311961T patent/DE60311961T2/de not_active Expired - Lifetime
- 2003-01-07 BR BR0306723-8A patent/BR0306723A/pt not_active IP Right Cessation
- 2003-01-07 CA CA002472026A patent/CA2472026A1/en not_active Abandoned
- 2003-01-07 IL IL16272203A patent/IL162722A0/xx unknown
- 2003-01-07 EP EP15158266.5A patent/EP2913407B1/en not_active Expired - Lifetime
-
2004
- 2004-06-24 IL IL162722A patent/IL162722A/en not_active IP Right Cessation
- 2004-06-30 NO NO20042769A patent/NO20042769L/no not_active Application Discontinuation
-
2007
- 2007-05-21 CY CY20071100705T patent/CY1106621T1/el unknown
-
2008
- 2008-08-14 AU AU2008205436A patent/AU2008205436A1/en not_active Abandoned
-
2009
- 2009-06-12 US US12/483,860 patent/US8420314B2/en not_active Expired - Fee Related
- 2009-06-12 US US12/483,900 patent/US7812144B2/en not_active Expired - Lifetime
-
2010
- 2010-01-04 JP JP2010000207A patent/JP5204132B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-11 US US13/792,414 patent/US20130309658A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2913407T3 (da) | Fremgangsmåde til at detektere human papillomavirus mRNA | |
| AU2010200955B2 (en) | Detection of human papillomavirus | |
| ZA200404971B (en) | Method for detecting human papillomavirus mRNA. | |
| HK1065827B (en) | Method for detecting human papillomarvirus mrna | |
| WO2003020975A2 (en) | OLIGONUCLEOTIDES FOR USE IN DETECTION OF HUMAN PAPILLOMAVIRUS L1 mRNA | |
| HK1090956B (en) | Detection of human papillomavirus |